RE:RE:Dilution? Doubt it.Institutions use different terms. Basically a corporate draw-down bridge line of credit convertible into equity after a period of time to avoid putting out lots of paper at unreasonably low share prices.
Equity facility, contingent equity line, contingent capital, and convertible loan / line could be alternate terms used to describe essentially the same thing.
But they may not even need this depending on FDA meeting in 6 weeks and pilot production ramp-up. Still good to have as a backup even if they don't use the facility.
In this case where SP has obvious potential to rise several-fold over the coming months the draw-down line lets the company pick its market timing for a PP or allows the sp to rise enough to trigger warrants or an alternate PP at higher prices allowing repayment of the original loan.
Conversion rate is favorable to the lender but seldom needs implementing as the company is motivated to and has options to repay before conversion timeframe is met.
Basically it is a bridge loan based on the tech validity, market potential and approval pipeline. Good strategy in a lame market.
If they announce such a facility expect the SP to jump as their next meeting with FDA is in 6 weeks, pilot production starts anytime, and the end of the FDA process is in sight. They estimated 12 months to approval after their initial FDA meeting 6 months ago.
Getting down to the short strokes now.
Cheers.
Merc
eunice12 wrote: What is an "equity line of credit"? This is not a residence where you can get a home equity line of credit.
No fund is going to give money to IME for anything but shares at the maximum 20% discount plus warrants - a LOC for interest is not possible.